Clinical Trial Update: Canakinumab in Patients With COVID-19 and Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating canakinumab in patients with COVID-19 and type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection
• Type 2 Diabetes Mellitus

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Coronavirus Infection, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED